Download PDF
Am J Perinatol 2017; 34(12): 1219-1226
DOI: 10.1055/s-0037-1602421
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Effect of Low-Dose Aspirin on the Time of Onset of Preeclampsia and Time of Delivery

C. Luke Dixon
1   Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, Texas
,
Caroline Marrs
1   Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, Texas
,
Maged M. Costantine
1   Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, Texas
,
Luis D. Pacheco
1   Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, Texas
,
George R. Saade
1   Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, Texas
,
Giuseppe Chiossi
1   Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, Texas
› Author Affiliations
Further Information

Publication History

23 December 2016

27 March 2017

Publication Date:
26 April 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Objective To determine whether low-dose aspirin (LDA) affects the time of onset of preeclampsia and the time of delivery in high-risk women.

Study Design Secondary analysis of a multicenter randomized controlled trial of LDA (60 mg) in high-risk women. Quantile regression was used to identify the median gestational age at preeclampsia diagnosis and median gestational age at delivery, whereas logistic regression was used to determine the likelihood of preeclampsia-indicated delivery within 7 days.

Results Total of 2,479 women were randomized and 461 developed preeclampsia. The mean gestational age at enrollment was 20 ± 4 weeks. On multivariate analysis, LDA did not affect the time of preeclampsia diagnosis (coefficient −0.4 weeks, 95% CI: −1.1 to 0.2; p = 0.2), time of delivery (coefficient 0 weeks, 95% CI: −0.3 to 0.3; p = 1), or likelihood of preeclampsia-indicated delivery within 7 days (OR = 0.8; 95% CI: 0.5–1.2; p = 0.2). In multifetal gestations, preeclampsia was diagnosed at least 1 week earlier than women with diabetes or previous preeclampsia (p < 0.05), and delivery occurred at least 2 weeks prior (p < 0.001).

Conclusion LDA prophylaxis did not significantly affect time of diagnosis of preeclampsia, time of delivery, or likelihood of preeclampsia-indicated delivery within 7 days. LDA prophylaxis did not significantly affect time of diagnosis of preeclampsia, time of delivery, or likelihood of preeclampsia-indicated delivery within 7 days.

Keywords

preeclampsia - low - dose - aspirin - prevention
 

  • References

  • 1 American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122 (05) 1122-1131
    CrossrefPubMedSearch in Google Scholar
  • 2 Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ 2013; 347: f6564 . Doi: 10.1136/bmj.f6564
    CrossrefPubMedSearch in Google Scholar
  • 3 Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006; 195 (01) 40-49
    PubMedSearch in Google Scholar
  • 4 Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet 1986; 1 (8471): 1-3
    PubMedSearch in Google Scholar
  • 5 North RA, McCowan LM, Dekker GA. , et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011; 342: d1875 . Doi: 10.1136/bmj.d1875
    CrossrefPubMedSearch in Google Scholar
  • 6 Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30 (1-2): 260-279
    CrossrefPubMedSearch in Google Scholar
  • 7 Grab D, Paulus WE, Erdmann M. , et al. Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol 2000; 15 (01) 19-27
    CrossrefPubMedSearch in Google Scholar
  • 8 Schiff E, Peleg E, Goldenberg M. , et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989; 321 (06) 351-356
    CrossrefPubMedSearch in Google Scholar
  • 9 Sibai BM, Caritis SN, Thom E. , et al; The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med 1993; 329 (17) 1213-1218
    CrossrefPubMedSearch in Google Scholar
  • 10 Rotchell YE, Cruickshank JK, Gay MP. , et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol 1998; 105 (03) 286-292
    CrossrefPubMedSearch in Google Scholar
  • 11 Vainio M, Kujansuu E, Iso-Mustajärvi M, Mäenpää J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002; 109 (02) 161-167
    CrossrefPubMedSearch in Google Scholar
  • 12 Villa PM, Kajantie E, Räikkönen K. , et al; PREDO Study group. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO trial and a meta-analysis of randomised trials. BJOG 2013; 120 (01) 64-74
    PubMedSearch in Google Scholar
  • 13 Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH. ; Fetal Medicine Foundation Second Trimester Screening Group. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet Gynecol 2003; 22 (03) 233-239
    CrossrefPubMedSearch in Google Scholar
  • 14 Caritis S, Sibai B, Hauth J. , et al; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998; 338 (11) 701-705
    CrossrefPubMedSearch in Google Scholar
  • 15 LeFevre ML, Force USPST. ; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 161 (11) 819-826
    CrossrefPubMedSearch in Google Scholar
  • 16 Zahn C, Wax J, Porter T. Practice Advisory on Low-Dose Aspirin and Prevention of Preeclampsia: Updated Recommendations website. http://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Low-Dose-Aspirin-and-Prevention-of-Preeclampsia-Updated-Recommendations . July 11, 2016 . Accessed September 5, 2016.
    PubMedSearch in Google Scholar
  • 17 CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343 (8898): 619-629
    CrossrefPubMedSearch in Google Scholar
  • 18 Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014; 160 (10) 695-703
    CrossrefPubMedSearch in Google Scholar
  • 19 Park F, Russo K, Williams P. , et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol 2015; 46 (04) 419-423
    CrossrefPubMedSearch in Google Scholar
  • 20 Fagerland MW, Hosmer DW, Bofin AM. Multinomial goodness-of-fit tests for logistic regression models. Stat Med 2008; 27 (21) 4238-4253
    CrossrefPubMedSearch in Google Scholar
  • 21 Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; (02) CD004659 . Doi: 10.1002/14651858.CD004659.pub2
    PubMedSearch in Google Scholar
  • 22 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, Group PC. ; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369 (9575): 1791-1798
    CrossrefPubMedSearch in Google Scholar
  • 23 Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216 (02) 110-120.e6
    CrossrefPubMedSearch in Google Scholar
  • 24 Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017; 216 (02) 121-128.e2
    CrossrefPubMedSearch in Google Scholar
  • 25 Ahrens KA, Silver RM, Mumford SL. , et al. Complications and safety of preconception low-dose aspirin among women with prior pregnancy losses. Obstet Gynecol 2016; 127 (04) 689-698
    CrossrefPubMedSearch in Google Scholar
  • 26 Pinar H, Sung CJ, Oyer CE, Singer DB. Reference values for singleton and twin placental weights. Pediatr Pathol Lab Med 1996; 16 (06) 901-907
    Search in Google Scholar
  • 27 Conti E, Zezza L, Ralli E. , et al. Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards?. Cytokine Growth Factor Rev 2013; 24 (05) 411-425
    CrossrefPubMedSearch in Google Scholar
  • 28 Powers RW, Jeyabalan A, Clifton RG. , et al; Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One 2010; 5 (10) e13263 . Doi: 10.1371/journal.pone.0013263
    CrossrefPubMedSearch in Google Scholar
  • 29 Festa A, D'Agostino Jr R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102 (01) 42-47
    CrossrefPubMedSearch in Google Scholar
  • 30 Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006; 11 (05) 309-316
    CrossrefPubMedSearch in Google Scholar
  • 31 Harrison DG, Guzik TJ, Lob HE. , et al. Inflammation, immunity, and hypertension. Hypertension 2011; 57 (02) 132-140
    CrossrefPubMedSearch in Google Scholar
  • 32 Cottam DR, Mattar SG, Barinas-Mitchell E. , et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 2004; 14 (05) 589-600
    CrossrefPubMedSearch in Google Scholar